CD BioGlyco
SUITE 201, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-637-6119 | Email: info@bioglyco.com

# Product Information

## PLL agent, Lentinan-PEG-poly-L-lysine, Purity ≥95%

**Cat. No.:** X25-05-YM711

**Size:** 100 mg; 250 mg; 500 mg; 1 g; 5 g

**Synonym:** Lentinan-PEG-poly-L-lysine; Poly-L-lysine-PEG-Lentinan

**This product is for research use only and is not intended for diagnostic use.**

## Product Information

| | |
|---|---|
| **Description** | Lentinan-PEG-PLL, referenced as PLL-lentinan, engineers a poly-L-lysine-conjugated derivative *via* PEG-mediated attachment of cationic polymers to lentinan's glucan framework. This nucleic acid-complexing hybrid preserves triple-helix geometry while enhancing gene delivery for thymic immune cell engineering. |
| **Glycan Structure** | Its glycan structure is a β-(1→3)-linked d-glucose backbone with β-(1→6)-glucosyl side branches. |
| **Source** | Chemical synthesis |
| **Form** | Solid or powder |
| **Purity** | ≥95% |
| **Impurities** | No visible impurities to the naked eye. |
| **Solubility** | This product is soluble in most organic solvents, such as DCM, DMF, DMSO, and THF, and exhibits excellent solubility in water. |
| **Identity** | Confirmed by NMR. |
| **Stability** | It is stable under its storage temperature. |
| **Quality Level** | Research grade |
| **Applications** | Lentinan-PEG-poly-L-lysine can be used for its potential to study hematoporphyrin-PEG conjugates for light-activated drug release in precision oncology models. |
| **Storage** | Store at -20°C, protect from light and moisture. |